Pancreatic cancer treatment and research: an international expert panel discussion

Tempero, Margaret A.; Berlin, Jordan; Ducreux, Michel; Haller, D.G.; Harper, P.; Khayat, D.; Schmoll, H.-J.; Sobrero, Alberto; Cutsem, E. Van

doi:10.1093/annonc/mdq545

Cited by 57 publications

(44 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Overexpression of EGFR and its ligands is very common in pancreatic cancer, and it is linked to increased tumor aggressiveness and poor prognosis. Preclinical studies have shown that blocking EGFR signaling inhibits growth and metastasis of pancreatic tumors in xenograft models and synergistic activity has been documented when combined with gemcitabine (Tempero et al, 2011).…”

Section: Egfr-ras-mek-erk Pathwaymentioning

confidence: 99%

“…One potential explanation for this modest effect of EGFR inhibition in pancreatic cancer is the fact that KRAS mutations occur in 70-90% of these tumors (Tempero et al, 2011 Table 2. Selected phase III trials of targeted agents in advanced pancreatic cancer functions downstream of the EGFR signaling pathway, and mutations in the KRAS protein lead to constitutive activation independent of extracellular stimuli.…”

Section: Erlotinib Is An Oral Tyrosine Kinase Inhibitor [Tki] Againstmentioning

confidence: 99%

See 1 more Smart Citation

Current Perspectives and Future Trends of Systemic Therapy in Advanced Pancreatic Carcinoma

Estévez-García¹,

García‐Carbonero²

2012

Pancreatic Cancer - Clinical Management

View full text Add to dashboard Cite

Section: Egfr-ras-mek-erk Pathwaymentioning

confidence: 99%

Section: Erlotinib Is An Oral Tyrosine Kinase Inhibitor [Tki] Againstmentioning

confidence: 99%

Current Perspectives and Future Trends of Systemic Therapy in Advanced Pancreatic Carcinoma

Estévez-García¹,

García‐Carbonero²

2012

Pancreatic Cancer - Clinical Management

View full text Add to dashboard Cite

“…1 Median survival for patients after initial diagnosis is as short as 6 months. 2 Even in cases where the cancer is diagnosed at an early resectable stage, the 5-year survival is still only 22%. 3 Due to pancreatic cancer being one of the most malignant types of cancer to treat, a better understanding of the molecular mechanism involved in pancreatic cancer and subsequent identification of a specific molecular target are necessary to develop novel and more effective therapeutics.…”

Section: Introductionmentioning

confidence: 99%

Gambogic acid-loaded magnetic Fe3O4 nanoparticles inhibit Panc-1 pancreatic cancer cell proliferation and migration by inactivating transcription factor ETS1

Chen¹,

Wang²,

Zhang³

2012

IJN

View full text Add to dashboard Cite

Background: E26 transformation-specific sequence-1 (ETS1) transcription factor plays important roles in both carcinogenesis and the progression of a wide range of malignancies. Aberrant ETS1 expression correlates with aggressive tumor behavior and a poorer prognosis in patients with various malignancies. The aim of the current study was to evaluate the efficacy of a drug delivery system utilizing gambogic acid-loaded magnetic Fe 3 O 4 nanoparticles (GA-MNP-Fe 3 O 4 ) on the suppression of ETS1-mediated cell proliferation and migration in Panc-1 pancreatic cancer cells. Methods:The effects caused by GA-MNP-Fe 3 O 4 on the proliferation of Panc-1 pancreatic cancer cells were evaluated using a MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay while inhibition of tumor cell migration was investigated in a scratch assay. The expressions of ETS1, cyclin D1, urokinase-type plasminogen activator (u-PA), and VEGF (vascular endothelial growth factor) were examined by Western blot to elucidate the possible mechanisms involved. Results: In Panc-1 pancreatic cancer cells, we observed that application of GA-MNP-Fe 3 O 4 was able to suppress cancer cell proliferation and prevent cells from migrating effectively. After treatment, Panc-1 pancreatic cancer cells showed significantly decreased expression of ETS1, as well as its downstream target genes for cyclin D1, u-PA, and VEGF. Conclusion: Our novel finding reaffirmed the significance of ETS1 in the treatment of pancreatic cancer, and application of GA-MNP-Fe 3 O 4 nanoparticles targeting ETS1 should be considered as a promising contribution for better pancreatic cancer care.

show abstract

“…1 The disease is usually detected at an advanced stage, carries a poor prognosis regardless of treatment, and is associated with debilitating symptoms. After initial diagnosis, most patients have a median survival with treatment of about 6 months.…”

Section: Introductionmentioning

confidence: 99%

“…After initial diagnosis, most patients have a median survival with treatment of about 6 months. 1 Even in cases where the cancer is diagnosed at an early resectable stage, 5-year survival is still only 22%. 2 Advances in treating pancreatic cancer have been few and modest.…”

Section: Introductionmentioning

confidence: 99%

Study of the enhanced anticancer efficacy of gambogic acid on Capan-1 pancreatic cancer cells when mediated via magnetic Fe3O4 nanoparticles

Wang

Zhang²,

Chen³

et al. 2011

IJN

View full text Add to dashboard Cite

Background Gambogic acid (GA), a potent anticancer agent, is limited in clinical administration due to its poor water solubility. The aim of this study was to explore a drug delivery system based on magnetic Fe 3 O 4 nanoparticles (MNP-Fe 3 O 4 ) conjugated with GA to increase water solubility of the drug and enhance its chemotherapeutic efficiency for pancreatic cancer. Methods GA was conjugated with the MNP-Fe 3 O 4 colloidal suspension by mechanical absorption polymerization to construct GA-loaded MNP-Fe 3 O 4 , which acted as a drug delivery system. Results Combination therapy with GA and MNP-Fe 3 O 4 induced remarkable improvement in anticancer activity, which was demonstrated by optical microscopic observations, MTT assay, and nuclear DAPI staining. Furthermore, the possible signaling pathway was explored by Western blot. In Capan-1 pancreatic cancer cells, our observations demonstrated that this strategy could enhance potential anticancer efficiency by inducing apoptosis. The mechanisms of the synergistic effect may be due to reducing protein expression of Bcl-2 and enhancing that of Bax, caspase 9, and caspase 3. Conclusion These findings demonstrate that a combination of GA and MNPs-Fe 3 O 4 represents a promising approach to the treatment of pancreatic cancer.

show abstract

Pancreatic cancer treatment and research: an international expert panel discussion

Cited by 57 publications

References 31 publications

Current Perspectives and Future Trends of Systemic Therapy in Advanced Pancreatic Carcinoma

Current Perspectives and Future Trends of Systemic Therapy in Advanced Pancreatic Carcinoma

Gambogic acid-loaded magnetic Fe3O4 nanoparticles inhibit Panc-1 pancreatic cancer cell proliferation and migration by inactivating transcription factor ETS1

Study of the enhanced anticancer efficacy of gambogic acid on Capan-1 pancreatic cancer cells when mediated via magnetic Fe3O4 nanoparticles

Contact Info

Product

Resources

About